Published on
May 8, 2025
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty Makary, M.D. As head of the FDA’s oncology department, Richard Pazdur, M.D., represents the only FDA center director left from the …
Source:
Fierce Pharma
-
Neutral
